Pharmaceuticals, Biotechnology & Life Sciences

Merck KGaA names Kai Beckmann CEO to steer continuity amid volatile markets, balancing pharma, lab supplies and semiconductor growth while tackling AI‑driven R&D challenges.

FDA’s proposed removal of semaglutide and liraglutide from the 503B bulk‑list could boost Novo Nordisk’s pricing power, but raises competition and payer‑policy risks for investors to watch.

Teva’s Q1 2026 earnings show a 12% cash rise, strategic $700 m Emalex buy‑out, and a $500 m Blackstone‑backed duvakitug push, boosting R&D and niche revenue.

Read how Eli Lilly’s 2026 earnings forecast, Zepbound/Foundayo gains, and a $2.25 B gene‑editing partnership could boost investor confidence amid GLP‑1 competition.

Zoetis Q1 2026 highlights a 2.3 % revenue rise, AI‑driven biologic growth, and a ₹1.25/share dividend, underscoring strong cash flow and strategic partnerships.

Merck KGaA’s steady focus on biosafety testing keeps its shares steady amid market volatility, offering investors a reliable, cross‑sector growth outlook.

Pfizer’s interim MagnetisMM‑5 data show ELREXFIO improves progression‑free survival in RRMM, promising a premium price and strong market impact.

Agilent Technologies’ latest report shows how high‑margin RF modules fuel growth and offer a blueprint for pharma and biotech firms tackling market access, patent cliffs, and M&A in fast‑moving sectors.

Fosun Pharma partners with Arcera Life Sciences to accelerate neurodegenerative, oncology, and rare disease therapies—boosting global access to next‑gen drugs, including Alzheimer’s breakthroughs.

WuXi AppTec Q1 2024 earnings: 40% revenue growth, 70% profit jump, & a strong GLP‑1 pipeline, boosting margins and investor confidence.